Drug rash, eosinophilia, and systemic symptoms syndrome: Two pediatric cases demonstrating the range of severity in presentation--A case of vancomycin-induced drug hypersensitivity mimicking toxic shock syndrome and a milder case induced by minocycline.
BACKGROUND
Drug rash, eosinophilia, and systemic symptoms syndrome is a type of drug hypersensitivity reaction characterized by the clinical triad of skin eruption, fever, and internal organ involvement. Drug rash, eosinophilia, and systemic symptoms syndrome has rarely been reported in association with vancomycin or in the pediatric population. There have only been four pediatric case reports of drug rash, eosinophilia, and systemic symptoms syndrome and three cases of drug rash, eosinophilia, and systemic symptoms syndrome involving vancomycin published in the English literature to date.


METHODS
We describe two pediatric cases of drug rash, eosinophilia, and systemic symptoms syndrome to illustrate the range in severity of presentation. The first case illustrates drug rash, eosinophilia, and systemic symptoms syndrome associated with vancomycin exposure in a 14-yr-old boy with Duchenne muscular dystrophy after posterior spinal fusion, whose clinical presentation was indistinguishable from toxic shock syndrome. The second case illustrates a milder and more typical presentation of drug rash, eosinophilia, and systemic symptoms syndrome in a 14-yr-old boy being treated with minocycline for acne. We also present a review of the literature relevant to this syndrome.


CONCLUSIONS
: Drug rash, eosinophilia, and systemic symptoms syndrome is relatively unknown among general pediatricians and pediatric intensivists and may potentially become more common with the increasing use of long-term medications in the pediatric population. Our cases demonstrate the importance of an awareness of drug rash, eosinophilia, and systemic symptoms syndrome among general pediatricians and pediatric intensivists because drug rash, eosinophilia, and systemic symptoms syndrome may present in any range of severity, from indolent illness to frank and refractory shock.
Vinson
Amy E
AE
Department of Pediatrics, Rhode Island Hospital, Hasbro Children's Hospital, Providence, RI, USA. avinsonmd@gmail.com
Dufort
Elizabeth M
EM
Willis
Matthew D
MD
Eberson
Craig P
CP
Harwell
Joseph I
JI
D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D003937:Diagnosis, Differential; D004342:Drug Hypersensitivity / Q000175:diagnosis* / Q000503:physiopathology; D004802:Eosinophilia / Q000097:blood / Q000139:chemically induced* / Q000503:physiopathology; D005076:Exanthema / Q000139:chemically induced* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008911:Minocycline / Q000009:adverse effects*; D012720:Severity of Illness Index; D012772:Shock, Septic / Q000175:diagnosis*; D013577:Syndrome; D014640:Vancomycin / Q000009:adverse effects*
D000900:Anti-Bacterial Agents; D014640:Vancomycin; D008911:Minocycline